The Advanced Imaging and Dosimetry Core (AIDC) provides the infrastructure, resources, and expertise required to facilitate quantitative multiscale imaging and dosimetry calculations, which are required to optimally synergize the combination of molecular targeted radionuclide therapy (TRT) and immunotherapy (ImmRx). The AIDC is a centralized dosimetry service that will ensure consistent scientific rigor and dosimetry reporting across each of the Projects of this PO1 proposal, entitled ?Molecular targeted radionuclide therapy for tumor immunomodulation and enhancing immunotherapy response?. Furthermore, the significance of centralizing this process for each Project is the tremendous gain in efficiency that are achieved, ultimately saving individual investigators time and effort. Additionally, the AIDC will expand the leadership and operation of the Small Animal Imaging and Radiotherapy Facility (SAIRF) by offering support in all stages of the imaging and TRT dosimetry process, including calibration, experimental design, image acquisition optimization, pharmacokinetic profiling and modeling, micro-and macroscopic 3D dose calculations, and treatment response assessment. The AIDC will emphasize quality assurance and quality control in all aspects of the imaging and dosimetry process so that results are validated for application to the FDA. The AIDC will collaborate closely with the Radionuclide Production and Radiochemistry Core (RPRC) for dose calibration and traceability of the radiopharmaceuticals; and, the AIDC will collaborate with the Biostatistics and Bioinformatics Core (BBC) to help interpret imaging and dosimetry findings to validate response assessment. Lastly, the AIDC will help investigators disseminate their findings to the scientific community through publications and conference presentations. Renowned experts in the field of TRT dosimetry, Professor Bryan Bednarz and Joseph Grudzinski, will lead administrative and technical efforts, respectively.
- ADVANCED IMAGING AND DOSIMETRY CORE 2 The Advanced Imaging and Dosimetry Core (AIDC) will provide dedicated expertise and cost-efficient support required to facilitate quantitative multiscale imaging and dosimetry calculations for the P01 application, ?Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response.? This centralized dosimetry service core is critical for the P01 to achieve its overarching research goals of 1) developing a broad mechanistic understanding of the immunomodulatory capacity of molecular targeted radionuclide therapy (TRT) and 2) evaluating TRT as part of the next generation immunotherapy approaches to improve the treatment of immunologically ?hot? and ?cold? tumors.